Cambium Bio (ASX:CMB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Cambium Bio (ASX:CMB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Access Letter and Online Meeting Guide
Notice of Annual General Meeting and Proxy form
Proposed issue of securities - CMB
Corporate Presentation - September 2026
Date of AGM and Closing Date for Director Nominations
Notification of cessation of securities - CMB
Notification regarding unquoted securities - CMB
Cambium Bio Secures A$10.85 Million Funding Package
Cambium Bio secures conditional A$7.1 million placement for Elate Ocular Phase 3 program
Proposed issue of securities - CMB
Notice of ceasing to be a substantial holder
Change in Substantial Holding
Update - Proposed issue of securities - CMB
Notification regarding unquoted securities - CMB
Proposed issue of securities - CMB
FY26 Appendix 4G and Corporate Governance Statement
FY26 Appendix 4E and Annual Report
Cambium Bio advances Elate Ocular Phase 3 trial with FDA single pivotal study pathway amid AUD 4.1M loss
Change in Company Secretary and Communication Person
Updated Securities Trading Policy
Quarterly Activities/Appendix 4C Cash Flow Report
Cambium Bio advances Phase 3 trial preparations for Elate Ocular with FDA IND amendment submitted and funding initiatives underway
Change in substantial holding - BW
Cleansing Notice
Application for quotation of securities - CMB
Proposed issue of securities - CMB
Cambium Bio Raises A$1.0 Million via Placement
Cambium Bio Raises A$1 Million via Placement to Strategic Shareholder for Phase 3 Trial
